Electromed, Inc. Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures, and markets airway-clearance products using High Frequency Chest Wall Oscillation therapy, including the SmartVest system. The company sells to home-care, institutional, government, and international customers. This unaudited quarterly report covers the three and six months ended December 31, 2012, the second quarter of fiscal 2013, with comparisons to the prior-year periods.
Key Financial Metrics
| Metric | Three Months Ended Dec. 31, 2012 | Three Months Ended Dec. 31, 2011 | Six Months Ended Dec. 31, 2012 | Six Months Ended Dec. 31, 2011 |
|---|---|---|---|---|
| Net revenues | $3.856 million | $4.790 million | $7.888 million | $10.169 million |
| Gross profit | $2.514 million | $3.481 million | $5.335 million | $7.551 million |
| Gross margin | 65.2% | 72.7% | 67.6% | 74.2% |
| Operating income (loss) | $(595,414) | $100,142 | $(691,783) | $552,604 |
| Net income (loss) | $(411,191) | $24,554 | $(482,299) | $270,093 |
| Basic and diluted EPS | $(0.05) | $0.00 | $(0.06) | $0.03 |
For the six months ended December 31, 2012, operating cash flow was $1.202 million, compared with cash used in operations of $1.533 million in the prior-year period. Investing cash flow was $(510,214), primarily for $482,122 of property and equipment purchases. Financing cash flow was $(1.389) million, including $1.168 million of revolving-credit repayments and $220,871 of long-term debt payments. Cash and cash equivalents declined to $1.006 million at December 31, 2012 from $1.702 million at June 30, 2012.
At December 31, 2012, total assets were $19.144 million and total liabilities were $4.460 million. Accounts receivable were $9.725 million, inventories were $1.899 million, and current assets were $14.250 million. Total debt consisted principally of $600,000 outstanding on the revolving line and approximately $1.357 million of long-term debt, excluding current maturities. The warranty reserve increased to $661,000 from $610,000 at June 30, 2012.
Material Changes Versus the Prior Comparable Period
- Total revenue declined 19.5% in the quarter and 22.4% for the six-month period. Home-care revenue declined 22.6% and 26.8%, respectively, primarily because of pricing pressure, additional third-party payer procedures, longer claim approvals, reduced sales staffing, and clinical-area-manager turnover.
- International revenue increased 8.3% for the quarter and 38.4% for the six months, primarily due to higher Middle East sales. Government and institutional revenue increased 6.7% and 31.2%, respectively.
- Gross margin declined substantially because lower revenue reduced manufacturing-cost leverage. Management expects margins to return to historical levels above 70% as sales grow.
- SG&A declined 4.2% in the quarter and 10.9% for the six months, while research and development declined 56.4% and 55.0%, respectively. Cost reductions included lower travel, marketing, compensation, and external-vendor spending.
- The company moved from modest profitability to losses, with the six-month net result changing from $270,093 of income to a $482,299 loss.
- Accounts receivable and inventories declined by $1.126 million and $493,000, respectively, supporting positive operating cash flow. The company used that cash, together with existing liquidity, to reduce revolving debt.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management is pursuing full staffing of U.S. sales regions, a revised sales compensation plan, updated branding, international distributor expansion, and a newly hired international sales manager. It expects long-term research and development spending of approximately 5% of sales.
- Management believes cash and available borrowings will provide adequate liquidity for the next year, but states that additional financing may be required if operating performance or capital needs deteriorate.
- The credit facility was amended on February 13, 2013 after the company violated financial and nonfinancial covenants, including fixed-charge coverage, leverage, and chief-executive-officer provisions. The bank waived the specified defaults.
- The amendment reduced the revolving commitment from $6.0 million to $2.5 million, increased the applicable interest spread to LIBOR plus 3.50%, required monthly financial reporting, and modified covenant requirements, including minimum EBITDA thresholds for future quarters. The revolving line expires December 31, 2013 unless renewed.
- The company had approximately $1.9 million of net unused revolver availability as of February 13, 2013, subject to borrowing-base limitations. The filing does not provide a clear value for total remaining borrowing capacity independent of those limitations.
- Professional fees increased partly because of shareholder-proposal litigation and information-technology consulting. The company filed litigation against a shareholder-proposal proponent and a former chairman and chief executive officer; counterclaims were also filed.
- Key risks include reimbursement-policy changes, regulatory compliance and approvals, competition, international expansion, sales-force recruitment and retention, intellectual-property protection, litigation, credit-market conditions, and general economic conditions.
- The company estimated a federal research and development tax credit following its January 2013 extension by Congress; the expected effect was to be recorded in the quarter ending March 31, 2013.
Investor Verification Checklist
- Verify the February 13, 2013 waiver and fourth amendment, including covenant thresholds, minimum EBITDA requirements, borrowing-base limits, interest rate, and December 31, 2013 maturity.
- Assess whether home-care revenue and payer approval delays are stabilizing and whether sales-force changes can restore volume and pricing.
- Reconcile positive operating cash flow with the six-month net loss and determine the sustainability of working-capital benefits.
- Monitor liquidity, revolver availability, debt maturities, and compliance with the revised covenants.
- Evaluate whether gross margins can recover above 70% as management expects.
- Review the shareholder and former-executive litigation, related legal costs, and any potential financial exposure.
- Confirm the timing and amount of the research and development tax credit and its effect on subsequent earnings.
- Review the $661,000 warranty reserve, revenue-recognition estimates, payer-related adjustments, and allowance for doubtful accounts.